论文部分内容阅读
一些新型免疫抑制剂已获准用于临床 ,另一些正进行临床试验阶段 ,它们同其他药物合用时可出现一些副作用。他克莫司 (FK50 6)与非甾体抗炎药 (NSAID)在药效上相互作用 ,还有些药物通过改变细胞色素 P450活性而显著影响他克莫司的药代动力学 ,这些均可使他克莫司的肾毒性增加。含氢氧化铝 (镁 )的抗酸药和考来烯胺可降低麦考酚酸的生物利用度 ,一些骨髓抑制药物可增加麦考酚酸、西罗莫司和胍立莫司的骨髓毒性。西罗莫司与环孢素合用时二者血药浓度均上升 ,吲哚美辛则可增加鼠抗 CD3单抗的中枢神经系统副作用
Some new immunosuppressive agents have been approved for clinical use, while others are undergoing clinical trials and may show some side effects when combined with other drugs. Tacrolimus (FK50 6) interacts pharmacologically with non-steroidal anti-inflammatory drugs (NSAIDs), and some drugs significantly affect the pharmacokinetics of tacrolimus by altering cytochrome P450 activity, all of which Increased nephrotoxicity of tacrolimus. Antacids containing aluminum hydroxide (magnesium) and cholestyramine reduce the bioavailability of mycophenolic acid and some myelosuppressive drugs increase the myelotoxicity of mycophenolic acid, sirolimus and guanidibalin . Both the plasma concentrations of sirolimus and cyclosporine rose, and indomethacin increased central nervous system side effects of the murine anti-CD3 mAb